Can a Pharma Drug Improve Autism Conditions?

There are no treatments for autism, but that’s not stopping research into the development of therapies for core symptoms of autism spectrum disorder. This week, London-based AMO Pharma reported Phase II results from its investigational glycogen synthase kinase 3 (GSK3) beta inhibitor, AMO-02 (tideglusib), which showed patients dosed with the medication during the trial experienced an improvement in social withdrawal, repetitive behaviors, daily living skills, memory and sleep quality.